COVID-19 @ NIBIB

NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will provide solutions to the COVID-19 pandemic.

NIBIB is administering the RADx® Tech and Advanced Technology Platforms (ATP) programs. These programs are part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. In addition, NIBIB is supporting other technology development, imaging approaches, and digital platforms to address the pandemic.

Rapid Acceleration of Diagnostics (RADx®) Tech and ATP Programs

Mesa Biotech point of care COVID test

The RADx® Tech and ATP programs are supporting late-stage development of innovative point-of-care, home-based tests, and clinical laboratory tests.

generic bar chart titled tests produced

Summary data on proposals submitted to the RADx® Tech and ATP Programs.

RADx Testing

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

COVID-19 Research across NIBIB

Intramural Research on COVID-19

NIBIB’s Dr. Kaitlyn Sadtler is a study lead and Principal Investigator working with NIH colleagues to test people who were infected with SARS-CoV-2 and developed antibodies but did not develop symptoms. Read about results from this study.

MRI of chest with arrows pointing to points on the lungs

Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about this resource.

Videos

View videos about RADx® Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

RADx® Tech/ATP programmatic or technical inquiries: info.radx@poctrn.org

All other RADx® Tech/ATP Applicants: RADxNIBIB@mail.nih.gov

SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov

All others: COVID19NIBIB@nih.gov

Related Resources

NIH COVID-19 website

NIBIB announces additional RADx Tech program Phase 2 awards

Learn about clinical trials for treatments and vaccines at HHS Combat COVID

Director’s Message on COVID-19

NIH COVID-19 Information for Applicants/Grantees

Media Inquiries: nibibpress@mail.nih.gov or 301-496-3500

Related News

View All News
Lung autopsies of COVID-19 patients reveal treatment clues
NIBIB in the News
November 17, 2021
Lung autopsy and plasma samples from people who died of COVID-19 have provided a clearer picture of how the SARS-CoV-2 virus spreads and damages lung tissue. NIH scientists and their collaborators say the information, published in Science Translational Medicine, could help predict severe and prolonged COVID-19 cases, particularly among high-risk people, and inform effective treatments. Read more at NIH.gov.
When to Test offers free online tool to help individuals make informed COVID-19 testing decisions
Press Releases
November 3, 2021
smart phone in person's hands
The NIH RADx initiative today announced the launch of the When To Test Calculator for Individuals, a companion to the version for organizations introduced last winter. By responding to just a few prompts, the new individual impact calculator indicates whether a person should get a test—now or soon.
New HHS Actions Add to Biden Administration Efforts to Increase Access to Easy-to-Use Over-the-Counter COVID-19 Tests
Press Releases
October 25, 2021
hands holding COVID test
NIH is investing $70 million from the American Rescue Plan to help bring more high-quality, at-home tests onto the market in the U.S. in coordination with the FDA. NIH’s new Independent Test Assessment Program (ITAP) will establish an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing.
NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests
Press Releases
October 14, 2021
packaging and testing device
The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.
Communities Say "Yes!" to COVID Tests
NIBIB in the News
October 12, 2021
SARS-CoV-2, the virus that causes COVID-19, doesn’t always cause symptoms, but people who have asymptomatic infections can unknowingly spread the disease. These asymptomatic infections may cause up to half of the viral spread in the United States. Source: NIH.gov